莫达菲尼尔是一种非典型的中枢神经系统兴奋剂?
Melinda Hersey1, Gianluigi Tanda1
1Medication Development Program, NIDA-IRP, NIH, Baltimore, MD, United States.
Advances in pharmacology (San Diego, Calif.)
|March 11, 2024
概括
作为中枢神经系统兴奋剂的莫达菲尼尔表现出异常特性,为睡眠障碍,认知功能障碍和低依赖风险的物质使用障碍提供了潜在的益处.
科学领域:
- 神经科学是一个神经科学.
- 药理学 药理学是指药理学的学科.
- 精神病学是一个精神病学.
背景情况:
- 莫达菲尼尔是一种中枢神经系统 (CNS) 兴奋剂,已被批准用于麻醉症和睡眠障碍.
- 其广泛的生物化学作用表明,除了睡眠障碍之外,它还有潜在的治疗应用,包括认知功能障碍和物质使用障碍.
- 摩达菲尼尔疗效的确切作用机制在很大程度上仍未确定.
研究的目的:
- 概述莫达菲尼尔的药理动力学和药理动力学.
- 为了突出modafinil的批准和非标签用途.
- 探索莫达菲尼尔作为一种非典型的中枢神经系统兴奋剂的独特药理特征.
主要方法:
- 对modafinil的药理学现有文献的审查.
- 对药理动力学和药理动力学数据的分析.
- 对治疗用途的临床证据的审查.
主要成果:
- 莫达菲尼尔抑制多巴胺载体,影响多巴胺的再吸收.
- 尽管与成性精神兴奋剂有相似之处,但莫达菲尼尔的依赖率很低.
- 莫达菲尼尔在治疗物质使用障碍方面已证明有效.
- 莫达菲尼尔会影响其他神经递质系统 (GABA,谷氨酸,血清素,上腺素) 并激活特定的大脑区域.
结论:
- 莫达菲尼尔具有非典型的中枢神经系统刺激特征.
- 它独特的药理学支持其用于睡眠障碍,认知增强和物质使用障碍治疗.
- 对莫达菲尼尔复杂相互作用的进一步研究是有必要的,以充分理解其治疗潜力.
相关概念视频
01:25Adrenergic Agonists: Indirect-Acting Agents
1.6K
Indirect-acting adrenergic agonists potentiate the effects of endogenous catecholamines through different mechanisms without directly binding to adrenoceptors.
One mechanism involves depleting stored catecholamines by displacing them from synaptic vesicles. These agents, known as "displacers," are transported into vesicles at the expense of noradrenaline. Examples include amphetamine and tyramine, which lack a catechol moiety, resulting in prolonged action, improved oral...
One mechanism involves depleting stored catecholamines by displacing them from synaptic vesicles. These agents, known as "displacers," are transported into vesicles at the expense of noradrenaline. Examples include amphetamine and tyramine, which lack a catechol moiety, resulting in prolonged action, improved oral...
1.6K
01:22CNS Stimulants: Psychedelic Agents
151
Hallucinogens, also known as psychedelic drugs, are a class of substances known for their ability to alter perception, cognition, and emotions. Despite their profound effects on the mind, these drugs are non-addictive, setting them apart from many other abused substances. The mechanism of action of these drugs lies in their impact on the 5-HT2A receptor in the brain. Upon activation, this receptor couples to Gq-type G proteins, triggering a cascade that releases intracellular calcium. This...
151
01:24CNS Stimulants: Cocaine, Amphetamines and Cannabinoids
193
CNS stimulants, such as cocaine, amphetamines, and cannabinoids, have varying structures and mechanisms of action that lead to different therapeutic effects and side effects. Cocaine, with its molecular formula C17H21NO4, is a tropane alkaloid and a tertiary amino compound. It has two chemical forms: the hydrochloride salt and the "freebase." The former is in powder form, while the latter involves removing the hydrochloride salt to create a form that can be smoked. Cocaine exerts its...
193
01:30Cognitive Enhancers: Cholinesterase Inhibitors and NMDA Receptor Antagonists
125
Cognitive enhancers, also known as "smart drugs," are substances used to enhance memory, mental alertness, and concentration. These can be natural or synthetic and improve cognition in conditions like Alzheimer's disease (AD) and other neurodegenerative diseases. Some common examples include caffeine, amphetamines, methylphenidate, modafinil, arecoline, donepezil, vortioxetine, and piracetam. These enhancers work on the principle of synaptic plasticity and altered circuit function.
125
01:23Drugs Acting on Autonomic Ganglia: Stimulants
1.3K
Ganglionic stimulants activate NM nicotinic receptors in autonomic ganglia, falling into two categories: nicotine mimetics [e.g., lobeline, dimethylpiperazine, tetramethylammonium] and muscarinic receptor agonists [e.g., muscarine, methacholine]. The first category's action is rapid and blocked by nicotinic receptor antagonists, while the second category's action is delayed and blocked by atropine-like agents. Nicotine, an alkaloid, affects the heart rate by stimulating...
1.3K
01:28Adrenergic Agonists: Mixed-Action Agents
709
Mixed-action adrenergic agonists, like ephedrine and pseudoephedrine, directly and indirectly affect adrenergic receptors. These agents stimulate adrenoceptors and indirectly release stored neurotransmitters, amplifying the adrenergic response.
Ephedrine and pseudoephedrine lack a catecholamine group, making them less susceptible to degradation by metabolic enzymes. They have increased oral bioavailability and lipophilicity, resulting in a longer duration of action. Their response is reduced by...
Ephedrine and pseudoephedrine lack a catecholamine group, making them less susceptible to degradation by metabolic enzymes. They have increased oral bioavailability and lipophilicity, resulting in a longer duration of action. Their response is reduced by...
709